PRA Health Sciences Earns Recognition, Industry Awards
May 14 2019 - 7:00AM
PRA Health Sciences, Inc. is pleased to announce it has received an
array of awards and recognition during the first months of 2019.
On Saturday, May 4, PRA was recognized as the Clinical
Research Company of the Year – the Americas
by PharmaTimes. This is the seventh consecutive year that the
company has won this prestigious industry award.
Clinical Researcher of the Year – The
Americas is a real-world competition that recognizes
the talent and passion of industry and
academic researchers and is considered a key barometer of
quality standards in the clinical research organization (CRO)
industry. The multi-stage competition is organized by an
independent executive steering committee comprised of senior
industry leaders from big and small pharma, leading CROs, and
professional membership associations.
PRA accepted this honor during an awards ceremony in Boston,
MA.
In April, PRA was also named on the Forbes 2019 Best Large
Employers list, which recognizes the companies that have been
identified as being most liked by employees. Additionally,
this past January, PRA was named one of the best employers for
diversity by Forbes. This ranking recognizes organizations that
successfully cultivate cultures that welcome and support all
workers. Forbes partnered with market research
company Statista to create these annual rankings. “PRA is
very proud of the recognition we have received in recent days,”
said Colin Shannon, PRA’s Chief Executive Officer. “It is
gratifying to once again be recognized by our peers for our
commitment to improving and saving lives through new and innovative
treatments.” ABOUT PRA HEALTH SCIENCES
PRA Health Sciences is a full-service
global contract research organization, providing a broad range of
product development and data solution services to pharmaceutical
and biotechnology companies around the world. PRA’s integrated
services include data management, statistical analysis, clinical
trial management, medical writing and regulatory and drug
development consulting. PRA’s global operations span more than 70
offices across North America, Europe, Asia, Latin America, South
Africa, Australia and the Middle East, and over 15,800 employees
worldwide. Since 2000, PRA has participated in approximately 3,700
clinical trials worldwide. In addition, PRA has participated in the
pivotal or supportive trials that led to U.S. Food and Drug
Administration or international regulatory approval of more than 75
drugs. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES: Kate Reilly, Strategic Communications
Specialist, Global Marketing & Innovation EMAIL:
ReillyKate@prahs.com
PHONE: +1 919.786.8510
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Jun 2024 to Jul 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Jul 2023 to Jul 2024